Dr. Gill is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2005 - 2009- New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2005 - 2008
Icahn School of Medicine at Mount SinaiResidency, Internal Medicine/Pediatrics, 2001 - 2005
David Geffen School of Medicine at UCLAClass of 2001
Certifications & Licensure
FL State Medical License 2021 - Present
WA State Medical License 2023 - 2026
AZ State Medical License 2023 - 2025
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2023 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
- Join now to see all
Clinical Trials
- Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2011 Jul 18
- Metformin in Children With Relapsed or Refractory Solid Tumors Start of enrollment: 2012 Sep 24
- Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma Start of enrollment: 2012 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 16 citationsABBV-085, Antibody-Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium.Pooja Hingorani, Michael Roth, Yifei Wang, Wendong Zhang, Jonathan Gill
Molecular Cancer Therapeutics. 2021-03-01 - 10 citationsInitial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing ConsortiumDouglas J. Harrison, Jonathan D. Gill, Michael Roth, Wendong Zhang, Beverly A. Teicher
Pediatric Blood & Cancer. 2020-03-24 - 9 citationsTrastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.Pooja Hingorani, Wendong Zhang, Zhongting Zhang, Zhaohui Xu, Wei-Lien Wang
Molecular Cancer Therapeutics. 2022-08-02
Press Mentions
Sarcomas with Complex Genetic ChangesSeptember 10th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
